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Abstract
Background: Potential look-alike, sound-alike (LASA) errors in outpatient and inpatient prescriptions have been
widely described worldwide. However, most strategies of reducing drug name confusion have been only focused
on the processes of prescribing and dispensing, often following local rules.
Main text: An illustrative recent example about this topic is given: the antidepressant Brintellix® (vortioxetine)
(Takeda Pharmaceuticals USA, Inc.) and the antiplatelet medication Brilinta® (ticagrelor) (AstraZeneca LP). Revision of
the initiatives that are currently applied to prevent potential LASA errors in different countries around the world
and debate about the emerging strategies that could be implemented in short and mid-term. At present, a
common policy worldwide on the authorization of unique names for innovative medicines does not exist. The
implication of authorities in topdown strategies and the importance of developing an international health policy on
the authorization of unique names for innovative medicines are highlighted in the following piece of opinion.
Conclusions: Building and sustaining a culture of patient safety should be considered as a global top-down
strategy which involved all the elements in the system (regulatory bodies, manufacturers and suppliers). The
precedent established by the FDA in prevention strategies to identify and avoid LASA errors has been extremely
important and should lead to international discussion. Coordinated international efforts are urgently needed in this
area for the sake of patients’ safety.
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Background
Since the publication of the reports “To err is human:
building a safer health system” [1] by the Institute of
Medicine in the US in 1999 and “Building a safer NHS
for patients: improving medication safety” [2] by the
National Health Service in the UK in 2001, several stud-
ies have demonstrated the important role of health pro-
fessionals in the identification, prevention and reduction
of medication errors (ME) and the improvement of
safety and quality of patient care [3].
Look-Alike Sound-Alike (LASA) ME caused by the
phonetic-orthographic similarity between the names of
some medications may have undesirable or adverse
effects, especially in chronic polymedicated patients. For
instance, the United States Pharmacopeia recorded 26,
604 LASA errors between 2003 and 2006 through spon-
taneous notifications. In particular, 3170 pairs of drug
names that could potentially lead to LASA errors were
identified; 1.4% of them caused damage to the patient
[4]. Similarly, some observational studies suggested that
1% of prescriptions dispensed in the US are associated
with LASA errors [5].
Despite these recurrent safety concerns, there is no
common policy worldwide regarding the authorization
of unique names for innovative medicines. The main
reason could be related to the temporary lag that usually
exists between marketing authorizations in the US and
Europe, which difficult the tracking of brand names for
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innovations. This timeframe increases dramatically when
marketing authorizations are extended to other coun-
tries in the world, which also entails higher complexity
in terms of linguistics and phonetics. In addition to dif-
ferences between the US and Europe, there is also high
variability between countries of the European Union
(EU). In case of centralized marketing authorizations in
Europe, there is a working group in the European Medi-
cines Agency (EMA) with representatives of each na-
tional agency (27 countries) that ensure that the names
of these innovative medicines do not generate conflicts
in any countries. However, in case of other authorization
procedures different from centralized, the drug agencies
of each country check independently the names that are
proposed and reject them when they are similar to
others already used for marketed products in their own
country. This mechanism increases variability in brand
names between member states. Even though, paronyms
may still exist and homonymous names of medicines
from different countries with different compositions
could coincide. While there exist strategies for reducing
the risk of LASA errors and promoting the current de-
gree of evidence supporting specific ones, the underlying
problem still persists. Besides, it is worth mentioning the
additional difficulty of idiomatic variability, which could
identify LASA errors in different pairs depending on the
country of study.
In order to identify which strategies are applied to pre-
vent these potential ME in different countries around
the world, we carried out a literature review in PubMed
of ME related to LASA medicines applying the MeSH
terms (“drug labeling”, “medication errors”, “terminology
as topic”, “pattern recognition, visual”, “phonetics”, “rec-
ognition (psychology)”) and free terms, reaching a total
of 276 results.
Discussion
Case report of a medication error by look-alike names
The medicine named Brintellix® (vortioxetine) (Takeda
Pharmaceuticals USA, Inc.) represents an illustrative
recent example of this problem. Brilinta® (ticagrelor)
(AstraZeneca LP) was authorized by the FDA in July
2011 and Brintellix® (vortioxetine) (Takeda Pharmaceuti-
cals USA, Inc.) in September 2013. In the EU, ticagrelor
was authorized by the EMA under the name of Brilique®
(ticagrelor) in 2010 and Brintellix® (vortioxetine) in
December 2013. It should be stressed that Brintellix®
(vortioxetine) is subject to additional monitoring since it
contains a new active substance authorized in the EU
after 1st January 2011, and medicines usually remain
under additional monitoring for 5 years.
In July 2015, the FDA issued an alert regarding notifi-
cations of LASA errors involving two medicines in both
prescribing and dispensing. The drugs concerned were
the antidepressant Brintellix® (vortioxetine) and the anti-
platelet medication Brilinta® (ticagrelor) [6]. In May
2016, the FDA issued a new safety alert about the name
change of Brintellix® (vortioxetine) to Trintellix® (vor-
tioxetine) (Takeda Pharmaceuticals USA, Inc.), with
effect from June 2016 [6]. This decision was due to the
50 medication reports describing brand name confusion
with (Brintellix® (vortioxetine) and Brilinta® (ticagrelor))
which the FDA had received in just 21 months (between
September 2013 and June 2015). In 12 cases out of 50,
the wrong medication had been dispensed, though it was
not actually administered in any of the cases [6]. In
the remaining 38 reports, the error was detected be-
fore prescribing and/or dispensing and was classified
as a potential error.
The fact that the European authorities did not imple-
ment similar measures to those considered by the FDA
suggests that either ME of this type appear to have not
occurred in the EU, or that none were reported. The
first of these assumptions appears rather unlikely, taking
into account the rate of events reported in the US and
the variety of languages in the EU, which could signifi-
cantly increase the incidence of LASA errors. Thus, a
more likely explanation is that errors were not reported
in Europe.
At this point, a serious consideration should be advis-
able: What is the main reason to justify the lack of
reports in the EU about LASA errors? It could be related
to the complexity of the system, or to a culture that as-
sociates the error with a poor professional performance.
With the consolidation of the pharmacovigilance system
in EU countries, and since the competent authorities in
EU Member States are aware of the adverse reactions
associated with ME, the first explanation (the complexity
of the system) seems highly unlikely. The second explan-
ation (the association of the error with a poor profes-
sional performance) may be more difficult to solve
because it is a problem that is culturally ingrained. The
study by the American Pharmacist Association entitled
“Medication Errors” [7] and the book cited above “To
err is human: building a safer health system” [1] both
underline the existence of inherent error in human ac-
tivity, and stress the importance of seeking ways to iden-
tify and minimize these errors rather than handing out
punishments that do little, if anything, to improve the
situation.
Risk minimization activity
These reports laid the groundwork for patient safety culture
and raised the development of highly effective interven-
tions, even out of the hospital setting, such as outpatient
care, diagnostic errors, and the use of health information
technologies, which are emerging priorities in patient safety.
The one-size-fits-all best-practice approaches should be
Lizano-Díez et al. BMC Health Services Research           (2020) 20:63 Page 2 of 5
revisited, as most results have been modest and not trace-
able from place to place due to barriers in implementation
and daily practice. Specific tailored strategies should be
deployed after identifying the key causes of ME in each set-
ting, organization and country, promoting interdisciplinary
cooperation in healthcare setting [8]. The next challenge in
patient safety is the development and implementation of
tools and top-down strategies that enable organizations to
measure and reduce harm both inside and outside the hos-
pital. The National Pharmacy Association (NPA) in UK
and the Agency for Healthcare Research and Quality
(AHRQ) in the US are currently sponsoring programs in
this regard.
Although several countries have implemented strat-
egies for preventing these potential ME, the US has
been the pioneer for more than 20 years. Currently, it is
the country that has contributed by far most of the evi-
dence on the topic and prevention strategies, in the
field of pediatrics as well [9]. The studies published in
the UK [10] and some specific projects in Australia,
Brazil, Hong Kong, India, Iran, Israel and South Africa
are also noteworthy [11–17]. Some examples of confusing
names recorded were: cefuroxime-cefotaxime-ceftazidime,
doxorubicin-daunorubicin-idarubicin and carbamazepine-
oxcarbazepine-carbimazole, as nonproprietary names [11]
and Adderall®-Inderal®, PD-Mox®-PD-Rox®, Clomine®-Clo-
zine®, Bioclox®-Biodoxi® and Zyrof®-Zyrop®, as brand
names [9, 14].
What now and what next
Most prevention strategies to identify LASA errors have
been developed at hospital setting. Some of the strategies
that have been proposed and tested to minimize risks in-
clude: 1) computer algorithms that detect potential
LASA errors by analyzing names, medication orders and
diagnostic claims data [18]; 2) changes in the appearance
of labeling and packaging of LASA medicines, paying
special attention to their differences (for example the
use of uppercase-lowercase letters, boldface or coloured
letters to highlight the differences between names;
coloured labeling and contrasting background) [19, 20];
3) inclusion of stickers with security symbols or picto-
grams on the packaging [19, 20]; 4) re-packaging [17]; 5)
bar-code-assisted medication administration [5]; 6) le-
gible manual prescription avoiding abbreviations [3]; 7)
avoiding oral and vague prescription [19]; 8) changing
order and separate storage of products with similar
name, with special attention in case of medicines with
narrow therapeutical margin [19]; 9) reminders and
alerts for LASA products [19]; 10) correct verification
before dispensing and/or administration [5, 19]; 11) the
joint use of the brand name and the generic name (in
brackets) in prescriptions and drug labeling [19]; 12) re-
view of new medications added in formularies and
changes in packaging resulting from contract changes or
drug shortages [19].
It is difficult to determine which risk minimisation
measures have the most significant impact and there ap-
pears to be a lack of good research in this area. More
evidence, especially from real-life setting is needed to
support safe labeling strategies and the solutions that are
not a sustainable solution to the wider LASA challenge.
In this sense, Schroeder et al. [21] provide evidence of
the association between laboratory-based tests of mem-
ory and perception and drug name confusing errors ob-
served in real world, which could be considered as a
prevention strategy. By contrast, other authors as Lam-
bert et al. [22] point out some methodological limita-
tions of Tall Man interventions to assess their benefits
as effective. Tall Man lettering is an error-prevention
strategy used to reduce the risk of look-alike medicine
names errors. Tall Man lettering uses a combination of
lower and upper case letters to highlight the differences
between look-alike medicine names, helping to make
them more easily distinguishable.
Many lists have been published in various countries
identifying pairs of names that could potentially produce
a LASA error. These lists are continuously being up-
dated in the healthcare organizations. As an example,
the Spanish delegation for the Institute for Safe Medica-
tion Practices has been working with the General Coun-
cil of Spanish Pharmacists (CGCOF) for more than 10
years to update a database of similar names of medicines
and active substances that led themselves to confusion.
Currently, this database comprises more than 700 pairs
of names [23]. In the field of pharmacy practice, for ex-
ample, the CGCOF’s health knowledge database (Bot
PLUS 2.0), which is commonly used in dispensing, in-
cludes alarms regarding the phonetic and orthographic
similarity between medicines.
At present, the emerging strategies that could be im-
plemented in short and mid-term are the following: 1)
the configuration of computer selection screens and
drop down menus in prescription systems to prevent
LASA names from appearing adjacent to each other and
thus avoid errors; 2) the design of an international sys-
tem for the validation of names for new drugs/medicines
which bears the issue of possible confusions in mind; 3)
automated dispensing by means of electronic devices
and serialization technology (DataMatrix code), which
makes the healthcare supply chain safer as well as more
efficient and accurate; 4) use of a closed-loop system
with barcode technology to enhance the readability of
look-alike labels [20]; 5) consideration of potential LASA
errors when ordering stocks; 6) stringent feedback of
LASA issues to FDA, EMA and pharmaceutical industry
via pharmacists from hospitals and other health profes-
sionals; 7) developing strategies to involve patients and
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their caregivers in reducing risks through information
(for example by means of apps that specify the indi-
cation for which the medicine has been prescribed
and expected appearance, nonproprietary and brand
names and potential medication side effects). Artificial
intelligence and automated methods will be one of
the most accurate tools in the next future to avoid
LASA errors and ME in general by minimizing hu-
man factors risk.
Conclusions
Although numerous prevention strategies are being
carried out to identify LASA errors, effective top-down
strategies for avoiding new LASA names need to be
developed. The precedent established by the FDA in this
field has been extremely important and should lead to
international discussion. Coordinated international ef-
forts are urgently needed in this area for the sake of
patients’ safety.
Nevertheless, the implication of all the elements in the
system is essential to ensure its success. Most of the
strategies focus only on the processes of prescribing and
dispensing, but it is vital that regulatory bodies, suppliers
and manufacturers should also be fully involved in re-
solving this serious problem.
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